Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen BCR-ABL Assay Receives CE Mark

NEW YORK (GenomeWeb) – Asuragen today announced its Quantidex BCR-ABL IS CMR Kit has received the CE-IVD mark. 

The firm is launching the kit for monitoring BCR-ABL1 transcript levels in chronic myeloid leukemia patients this week. According to Asuragen, the product improves upon other tests by attaining a sensitivity of MR4.7 while it allows direct reporting on the International Scale. Additionally, the assay enables detection of complete molecular response. 

BCR-ABL1 transcripts arise from a chromosomal translocation called the Philadelphia chromosome that is associated with CML. While tyrosine kinase inhibitors represent a personalized approach to treating CML, and quantitative BRC-ABL1 testing can be crucial in monitoring the effectiveness of TKI therapy, the lack of reporting on the IS has complicated patient monitoring and treatment, Asuragen said. 

Its assay "is a major step forward in providing labs with a BCR-ABL kit with class-leading sensitivity that keeps pace with the advances in TKI therapies and the need for IS standardization," Asuragen President and CEO Matthew McManus said in a statement. 

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.